BridgeBio Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
BridgeBio Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
PALO ALTO, Calif., Aug. 08, 2024 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) ("BridgeBio" or the "Company"), a commercial-stage biopharmaceutical company focused on genetic diseases, today announced that on August 6, 2024, the compensation committee of BridgeBio's board of directors approved equity grants to 17 new employees in restricted stock units for an aggregate of 71,859 shares of the Company's common stock. One-fourth of the shares underlying each employee's restricted stock units will vest on August 16, 2025, with one-twelfth of the remaining shares underlying each such employee's restricted stock units vesting on a quarterly basis thereafter, in each case, subject to each such employee's continued employment with the Company or one of its subsidiaries on such vesting dates. All of the above-described awards were made under BridgeBio's Amended and Restated 2019 Inducement Equity Plan (the "Plan").
加州帕洛阿爾託市,2024年8月8日(環球新聞社)——商業化生物醫藥公司BridgeBio Pharma, Inc.(納斯達克:BBIO)(以下簡稱「BridgeBio」或「公司」)專注於遺傳性疾病,並於今天宣佈,2024年8月6日,BridgeBio的董事會薪酬委員會通過股權授予方案,授予17名新員工共71,859股公司普通股的限制性股票單位。每名員工限制性股票單位的股票基數四分之一將於2025年8月16日之前批准,其餘的股票基數每個季度之後批准,每家公司或其子公司的員工員工於此類認購日繼續在公司或其子公司的就業情況下。所有上述獎項均根據BridgeBio的修訂和重申2019年引入權益計劃(以下簡稱「計劃」)授予。
The above-described awards were each granted as an inducement material to the employees entering into employment with the Company in accordance with Nasdaq Listing Rule 5635(c)(4) and were granted pursuant to the terms of the Plan. The Plan was adopted by BridgeBio's board of directors in November 2019, and amended and restated on February 10, 2023 and on December 13, 2023.
上述獎勵均根據Nasdaq上市規則5635(c)(4)條款,並根據計劃條款授予公司僱員作爲就業誘因。該計劃於2019年11月由BridgeBio的董事會通過,並於2023年2月10日和2023年12月13日進行了修訂和重申。
About BridgeBio Pharma, Inc.
關於BridgeBio Pharma股份有限公司。
BridgeBio Pharma, Inc. is a commercial-stage biopharmaceutical company founded to discover, create, test, and deliver transformative medicines to treat patients who suffer from genetic diseases. BridgeBio's pipeline of development programs ranges from early science to advanced clinical trials. BridgeBio was founded in 2015 and its team of experienced drug discoverers, developers and innovators are committed to applying advances in genetic medicine to help patients as quickly as possible. For more information visit bridgebio.com and follow us on LinkedIn and Twitter.
BridgeBio Pharma,Inc。是一家商業化階段的生物製藥公司,旨在發現、創造、測試和提供革新性藥物來治療遺傳性疾病的患者。BridgeBio的開發計劃管道涵蓋了從早期科學到愛文思控股臨床試驗的所有方面。BridgeBio成立於2015年,其一流的藥物發現、研發和創新團隊致力於將遺傳醫學的進步應用於儘快幫助患者。有關更多信息,請訪問 bridgebio.com和我們一起LinkedIn和頁面。推特.
BridgeBio Contact:
BridgeBio聯繫人:
Vikram Bali
contact@bridgebio.com
(650)-789-8220
Vikram Bali
contact@bridgebio.com
(650)-789-8220